Elevated white blood cell count at the time of recurrence diagnosis is an indicator of short survival in patients with recurrent cervical cancer

International Journal of Gynecological Cancer

Volumn 22, Issue 9, 2012, Pages 1545-1551

  Mabuchi, Seiji ^a   Matsumoto, Yuri ^a,b   Hamasaki, Toshimitsu ^c   Kawano, Mahiru ^a   Hisamatsu, Takeshi ^a   Mutch, David G ^b   Kimura, Tadashi ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c OSAKA UNIVERSITY   (Japan)

Author keywords

Leukocytosis; Neutrophilia; Recurrent cervical cancer; Survival; WBC

Indexed keywords

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; DISEASE FREE INTERVAL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LEUKOCYTE COUNT; LEUKOCYTOSIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; UTERINE CERVIX CANCER;

AGED; CARCINOMA, SQUAMOUS CELL; FEMALE; HUMANS; LEUKOCYTE COUNT; LEUKOCYTES; LEUKOCYTOSIS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RECURRENCE; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TIME FACTORS; UP-REGULATION; UTERINE CERVICAL NEOPLASMS;

EID: 84872297199     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e31826ea0eb     Document Type: Article

References (25)

1. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277-300.
2. Ajiki W, Tsukuma H, Oshima A. Research group for population-based cancer registration in Japan. Cancer incidence and incidence rates in Japan in 1999: estimates based on data from 11 population-based cancer registries. Jpn J Clin Oncol. 2004;34:352-356.
3. Höckel M, Dornhöfer N. Pelvic exenteration for gynaecological tumours: achievements and unanswered questions. Lancet Oncol. 2006;7:837-847.
4. Fokdal L, Tanderup K, Nielsen SK, et al. Image and laparoscopic guided interstitial brachytherapy for locally advanced primary or recurrent gynaecological cancer using the adaptive GEC ESTRO target concept. Radiother Oncol. 2011;100:473-479.
5. Powell ME. Modern radiotherapy and cervical cancer. Int J Gynecol Cancer. 2010;20:S49-S51.
6. Monk BJ, Sill MW, McMeekin DS, et al. Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 2009;27:4649-4655.
7. Long HJ 3rd. Management of metastatic cervical cancer: review of the literature. J Clin Oncol. 2007;25:2966-2974.
8. Omura GA, Blessing JA, Vaccarello L, et al. Randomized trial of cisplatin versus cisplatin plus mitolactol versus cisplatin plus ifosfamide in advanced squamous carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol. 1997;15:165-171.
9. Vermorken JB, Zanetta G, De Oliveira CF, et al. Randomized phase III trial of bleomycin, vindesine, mitomycin-C, and cisplatin (BEMP) versus cisplatin (P) in disseminated squamous-cell carcinoma of the uterine cervix: an EORTC Gynecological Cancer Cooperative Group study. Ann Oncol. 2001;12:967-974.
10. Mabuchi S, Isohashi F, Yoshioka Y, et al. Prognostic factors for survival in patients with recurrent cervical cancer previously treated with radiotherapy. Int J Gynecol Cancer. 2010;20:834-840.
11. Granger JM, Kontoyiannis DP. Etiology and outcome of extreme leukocytosis in 758 nonhematologic cancer patients: a retrospective, single-institution study. Cancer. 2009;115:3919-3923.
12. Sakka V, Tsiodras S, Giamarellos-Bourboulis EJ, et al. An update on the etiology and diagnostic evaluation of a leukemoid reaction. Eur J Intern Med. 2006;17:394-398.
13. Mabuchi S, Matsumoto Y, Isohashi F, et al. Pretreatment leukocytosis is an indicator of poor prognosis in patients with cervical cancer. Gynecol Oncol. 2011;122:25-32.
14. Tavares-Murta BM, Mendonça MA, Duarte NL, et al. Systemic leukocyte alterations are associated with invasive uterine cervical cancer. Int J Gynecol Cancer. 2010;20:1154-1159.
15. Garcia-Arias A, Cetina L, Candelaria M, et al. The prognostic significance of leukocytosis in cervical cancer. Int J Gynecol Cancer. 2007;17:465-470.
16. Mabuchi S, Okazawa M, Isohashi F, et al. Radical hysterectomy with adjuvant radiotherapy versus definitive radiotherapy alone for FIGO stage IIB cervical cancer. Gynecol Oncol. 2011;123:241-247.
17. Asano S, Urabe A, Okabe T, et al. Demonstration of granulopoietic factor(s) in the plasma of nude mice transplanted with a human lung cancer and in the tumor tissue. Blood. 1977;49:845-852.
18. Hirasawa K, Kitamura T, Oka T, et al. Bladder tumor producing granulocyte colony-stimulating factor and parathyroid hormone related protein. J Urol. 2002; 167:2130.
19. Takahashi H, Yasuda A, Ochi N, et al. Granulocyte-colony stimulating factor producing rectal cancer. World J Surg Oncol. 2008;6:70.
20. Mabuchi S, Matsumoto Y, Morii E, et al. The first 2 cases of granulocyte colony-stimulating factor producing adenocarcinoma of the uterine cervix. Int J Gynecol Pathol. 2010;29:483-487.
21. Matsumoto Y, Mabuchi S, Muraji M, et al. Squamous cell carcinoma of the uterine cervix producing granulocyte colony-stimulating factor: a report of 4 cases and a review of the literature. Int J Gynecol Cancer. 2010;20: 417-421.
22. Connor JP. Aggressive carcinosarcoma of the uterine cervix associated with high levels of granulocyte colony stimulating factor: case report and laboratory correlates. Gynecol Oncol. 2006;103:349-353.
23. Shameem IA, Kurisu H, Matsuyama H, et al. Direct and indirect effects of recombinant human granulocyte-colony stimulating factor on in vitro colony formation of human bladder cancer cells. Cancer Immunol Immunother. 1994;38:353-357.
24. Tachibana M, Miyakawa A, Uchida A, et al. Granulocyte colony-stimulating factor receptor expression on human transitional cell carcinoma of the bladder. Br J Cancer. 1997;75:1489-1496.
25. Shojaei F, Wu X, Qu X, et al. G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models. Proc Natl Acad Sci U S A. 2009;106:6742-6747.